The decrease in frequencies and expression levels of CXCR4+ and CXCR5+ CLL B cells after CIT may contribute to the increased efficacy of this treatment in reduction of leukemic B cell tumor burden. Here, CXCR5 is linked to B-cell chronic lymphocytic leukemia.